The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
B Chowbay, A Sharma, QY Zhou… - Oncology …, 2003 - spandidos-publications.com
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
B Chowbay, A Sharma, QY Zhou, YB Cheung… - Oncology …, 2003 - europepmc.org
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
[引用][C] The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
B CHOWBAY, A SHARMA, QY ZHOU… - Oncology …, 2003 - pascal-francis.inist.fr
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different
classes of pharmacologic agents CNRS Inist Pascal-Francis CNRS Pascal and Francis …
classes of pharmacologic agents CNRS Inist Pascal-Francis CNRS Pascal and Francis …
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
B Chowbay, A Sharma, QY Zhou, YB Cheung, EJD Lee - 2003 - scholarbank.nus.edu.sg
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
[PDF][PDF] The modulation of irinotecan-induced diarrhoea and pharmaco-kinetics by three different classes of pharmacologic agents
B CHOWBAY, A SHARMA, QYU ZHOU… - ONCOLOGY …, 2003 - Citeseer
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
The modulation of irinotecan-induced diarrhoea and pharmaco kinetics by three different classes of pharmacologic agents
AS BALRAMCHOWBAY, QYU ZHOU… - ONCOLOGY …, 2003 - ingentaconnect.com
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents
B Chowbay, A Sharma, QY Zhou… - Oncology …, 2003 - pubmed.ncbi.nlm.nih.gov
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …
clinical setting. This study was designed to evaluate the effects of different pharmacological …